Phase I study of escalating doses of carfilzomib with HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia

AMERICAN JOURNAL OF HEMATOLOGY

WILEY

1. Takeda
2. UCDCCC Support Grant - National Cancer Institute [NCI P30CA093373]
3. University of California, Davis Comprehensive Cancer Center (UCDCCC) Office of Clinical Research